



PROGRESS WITH INJECTABLE THERAPIES: EVIDENCE, EXPERIENCE, AND EVOLVING TARGETS

TUESDAY, 12 MAY 2026

16:15-17:45

HALL 3,
ISTANBUL CONGRESS CENTER

PROGRAM

WELCOME AND INTRODUCTION



**Barbara McGowan, MA, MBBS,
PhD, MRCP, FRCP**
London, United Kingdom

THE SCIENCE BEHIND INJECTABLE THERAPIES: METABOLIC MECHANISMS AND THE EVOLUTION OF OBESITY MANAGEMENT MEDICATIONS



Tamer Coskun, MD, PhD
Indiana, United States

▼ TIRZEPATIDE: BUILDING THE EVIDENCE FOR SIGNIFICANT, SUSTAINED EFFICACY WITH AN INJECTABLE



**Barbara McGowan, MA, MBBS,
PhD, MRCP, FRCP**
London, United Kingdom

TIRZEPATIDE'S PROGRAM IN PRACTICE: NEW EVIDENCE, EVOLVING TARGETS, AND EFFECTS BEYOND THE SCALE



**Carel le Roux, MBChB, MSc,
FRCP, FRCPath, PhD**
Dublin, Ireland

TIRZEPATIDE'S CARDIOMETABOLIC EVIDENCE: WHAT THE DATA SHOW



Stefano Del Prato, MD
Pisa, Italy

DISCUSSION

All

CLOSING REMARKS



**Barbara McGowan, MA, MBBS,
PhD, MRCP, FRCP**
London, United Kingdom

▼ THIS MEDICINAL PRODUCT IS SUBJECT TO ADDITIONAL MONITORING.
FOR MORE DETAILED INFORMATION, PLEASE REFER TO THE SUMMARY OF PRODUCT CHARACTERISTICS (SMPC).



TIRZEPATIDE EMA SMPC



TIRZEPATIDE TÜRKİYE SMPC

Lilly A MEDICINE COMPANY

CMAT-22706 04/2026. www.lilly.com/tr